CSF samples (20–40 mL) were collected during the tap tests and collected in 14 mL polypropylene tubes, divided into aliquots of 250 µL, and immediately frozen at − 80 °C until analysis. CSF Aβ1–42, t-tau and p-tau were quantified at the UEF Biomarker Laboratory. Samples were analyzed either with ELISA assays (before 2020, assays Innotest β-amyloid (1–42), Innotest hTAU-Ag, and Innotest Phospho-Tau (181P), Fujirebio Europe, 30–33) or with automated immunoassays (since 2020, assays Elecsys β-Amyloid (1–42) CSF, Elecsys Total Tau CSF, and Elecsys Phospho-Tau (181P) CSF, Roche Diagnostics, 34–35). Due to measurement level differences between Innotest and Elecsys methods [36 (link)], the following conversions were performed to enable direct comparison of the results: Aβ1–42 Elecsys = (1.22 × Aβ1-42 Innotest) + 7.15, t-tau Elecsys = (0.475 × t-tau Innotest) + 66.0, p-tau Elecsys = (0.419 × p-tau Innotest)—3.807). These conversion factors had previously been established by measuring 100 CSF samples with Innotest and Elecsys assays.
Elecsys total tau csf
Manufactured by Roche
Elecsys® Total-tau CSF is an in vitro diagnostic test used to measure the total tau protein levels in cerebrospinal fluid (CSF) samples. This automated immunoassay is designed for use on the Elecsys and cobas e analyzers.
Automatically generated - may contain errors
Lab products found in correlation
Neurotoolkit, by Roche (4 mentions)
Cobas e601, by Roche (3 mentions)
Innotest β amyloid1 42, by Fujirebio (1 mentions)
Innotest htau ag, by Fujirebio (1 mentions)
Elecsys phospho tau 181p csf, by Roche (1 mentions)
Innotest phospho tau 181p, by Fujirebio (1 mentions)
Elecsys β amyloid 1 42 csf, by Roche (1 mentions)
Cobas e 601 instrument, by Roche (1 mentions)
Phospho tau 181p csf, by Roche (1 mentions)
5 protocols using elecsys total tau csf
1
Measurement of CSF Biomarkers for Alzheimer's
2
Cerebrospinal Fluid Biomarkers for Alzheimer's Continuum
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The collection of CSF and measurement of biomarkers in ALFA + was previously described comprehensively [12 ]. In brief, CSF t-tau and p-tau were measured using the electrochemiluminescence immunoassays Elecsys® Total-tau CSF and phosphor-tau(181P) CSF on a fully automated cobas e601 instrument (Roche Diagnostics International Ltd.). The rest of the CSF biomarkers were measured with robust prototype assay as part of the NeuroToolKit (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on both cobas e 601 and e 411 instruments. All measurements were performed at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Aβ pathology positivity (Aβ +) was defined by CSF Aβ42/40 ratio. We derived the cutoffs for each of these biomarkers using a two-Gaussian mixture modeling. The cut-off was defined as the mean plus 2 standard deviations (SD) of the non-pathologic Gaussian distribution (i.e., the Gaussian with the higher mean value for Aβ42/40 ratio and the resulting cutoff was 0.071. This approach for the definition of Aβ + has been shown to be optimal for the detection of pathophysiological changes in early stages of the Alzheimer’s continuum [17 ]. A total of 122 individuals in the study were categorized as Aβ + .
Aβ pathology positivity (Aβ +) was defined by CSF Aβ42/40 ratio. We derived the cutoffs for each of these biomarkers using a two-Gaussian mixture modeling. The cut-off was defined as the mean plus 2 standard deviations (SD) of the non-pathologic Gaussian distribution (i.e., the Gaussian with the higher mean value for Aβ42/40 ratio and the resulting cutoff was 0.071. This approach for the definition of Aβ + has been shown to be optimal for the detection of pathophysiological changes in early stages of the Alzheimer’s continuum [17 ]. A total of 122 individuals in the study were categorized as Aβ + .
3
Cerebrospinal Fluid Biomarker Measurement Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CSF samples were obtained by lumbar puncture following standard procedures [21 (link), 22 (link)]. Total tau and phosphorylated tau measurements were performed using the electrochemiluminescence immunoassays Elecsys® Total-tau CSF and Phospho-Tau(181P) CSF on a fully automated cobas e 601 instrument (Roche Diagnostics International Ltd.) [23 (link)]. Amyloid-β 42 (Aβ42) [24 (link)], amyloid-β 40 (Aβ40), neurofilament light (NfL), neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase-3-like protein 1 (YKL40), glial fibrillary acidic protein (GFAP), and α-synuclein were measured with the prototype NeuroToolKit (Roche Diagnostics International Ltd.) on a cobas e 411 instrument. Interleukin 6 (IL6) and calcium-binding protein B (S100B) were measured with the prototype NeuroToolKit (Roche Diagnostics International Ltd.) on a cobas e 601 instrument. All the measurements were conducted at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
4
Measurement of CSF Biomarkers
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CSF t‐tau and p‐tau were measured using the electrochemiluminescence immunoassays Elecsys® Total‐tau CSF and phosphor‐tau(181P) CSF on a fully automated cobas e601 instrument (Roche Diagnostics International Ltd.). The rest of the biomarkers were measured with the prototype NeuroToolKit (Roche Diagnostics International Ltd.) on a cobas e411 or e601 instrument (supporting information). All measurements were performed at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
5
Measuring Alzheimer's Biomarkers in CSF
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The collection of CSF and measurement of biomarkers in ALFA + was previously described comprehensively [12] (link). In brief, CSF t-tau and p-tau were measured using the electrochemiluminescence immunoassays Elecsys ® Total-tau CSF and phosphor-tau(181P) CSF on a fully automated cobas e601 instrument (Roche Diagnostics International Ltd.). The rest of the CSF biomarkers were measured with robust prototype assay as part of the NeuroToolKit (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on both cobas e 601 and e 411 instruments. All measurements were performed at the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Aβ pathology positivity (Aβ +) was defined by CSF Aβ42/40 ratio. We derived the cutoffs for each of these biomarkers using a two-Gaussian mixture modeling. The cut-off was defined as the mean plus 2 standard deviations (SD) of the non-pathologic Gaussian distribution (i.e., the Gaussian with the higher mean value for Aβ42/40 ratio and the resulting cutoff was 0.071. This approach for the definition of Aβ + has been shown to be optimal for the detection of pathophysiological changes in early stages of the Alzheimer's continuum [17] . A total of 122 individuals in the study were categorized as Aβ + .
Aβ pathology positivity (Aβ +) was defined by CSF Aβ42/40 ratio. We derived the cutoffs for each of these biomarkers using a two-Gaussian mixture modeling. The cut-off was defined as the mean plus 2 standard deviations (SD) of the non-pathologic Gaussian distribution (i.e., the Gaussian with the higher mean value for Aβ42/40 ratio and the resulting cutoff was 0.071. This approach for the definition of Aβ + has been shown to be optimal for the detection of pathophysiological changes in early stages of the Alzheimer's continuum [17] . A total of 122 individuals in the study were categorized as Aβ + .
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!